<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798287</url>
  </required_header>
  <id_info>
    <org_study_id>2011P002580-207</org_study_id>
    <nct_id>NCT04798287</nct_id>
  </id_info>
  <brief_title>Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints</brief_title>
  <acronym>STAR-RA-Cancer</acronym>
  <official_title>Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are two main aims of this study.&#xD;
&#xD;
      First aim is to compare the risk of composite cancer outcomes, between patients treated with&#xD;
      tofacitinib and patients treated with TNF inhibitors (TNFi) for rheumatoid arthritis (RA)&#xD;
      among, 1) &quot;real world evidence (RWE)&quot; cohorts including routine care patient population from&#xD;
      the US and, 2) &quot;Randomized controlled trial (RCT) DUPLICATE&quot; cohorts including routine care&#xD;
      patient population who meet inclusion and exclusion criteria of the Safety Study Of&#xD;
      Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid&#xD;
      Arthritis (&quot;ORAL Surveillance&quot;, NCT02092467) clinical trial.&#xD;
&#xD;
      Second aim is to examine the risk of common solid cancers (lung, colorectal, breast,&#xD;
      prostate), hematological cancers, and non-melanoma skin cancer as separated endpoints when&#xD;
      comparing tofacitinib with TNFi in patients with RA among, 1) &quot;real world evidence (RWE)&quot;&#xD;
      cohort including routine care patient population from the US and, 2) &quot;Randomized controlled&#xD;
      trial (RCT) DUPLICATE&quot; cohort including routine care patient population who meet inclusion&#xD;
      and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF)&#xD;
      Inhibitor In Subjects With Rheumatoid Arthritis (&quot;ORAL Surveillance&quot;, NCT02092467) clinical&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of any cancer (excluding NMSC and any carcinoma in situ diagnosis)</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of lung cancer (excluding any carcinoma in situ diagnosis)</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of colorectal cancer (excluding any carcinoma in situ diagnosis)</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of breast cancer (excluding any carcinoma in situ diagnosis)</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of prostate cancer (excluding any carcinoma in situ diagnosis)</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of lymphatic/hematopoietic tissue cancers</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of lymphoma</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second outpatient or inpatient diagnosis of leukemia</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first procedure code occurring within 60 days of an outpatient or inpatient diagnosis of NMSC</measure>
    <time_frame>Through study time period (2012-2020)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">105711</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients treated with Tofacitinib</arm_group_label>
    <description>Real-World Evidence (RWE) and RCT-Duplicate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with TNF inhibitors</arm_group_label>
    <description>Real-World Evidence (RWE) and RCT-Duplicate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>First eligible prescription for treating rheumatoid arthritis (RA)</description>
    <arm_group_label>Patients treated with Tofacitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNF Inhibitor</intervention_name>
    <description>First eligible prescription for treating rheumatoid arthritis (RA)</description>
    <arm_group_label>Patients treated with TNF inhibitors</arm_group_label>
    <other_name>infliximab</other_name>
    <other_name>adalimumab</other_name>
    <other_name>certolizumab pegol</other_name>
    <other_name>etanercept</other_name>
    <other_name>golimumab</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        There will be two independent study populations:&#xD;
&#xD;
          1. Real-World Evidence (RWE) cohorts: This study population will reflect the patients&#xD;
             diagnosed with RA who are routinely treated and managed in setting of clinical&#xD;
             practice.&#xD;
&#xD;
          2. RCT-duplicate cohorts: This study population will emulate &quot;the Safety Study Of&#xD;
             Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid&#xD;
             Arthritis&quot; clinical trial (&quot;ORAL Surveillance&quot;, NCT02092467). The inclusion and&#xD;
             exclusion criteria of this RCT will be applied to this study population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
        Please see https://www.bwhprime.org/resources.html for full code and algorithm definitions.&#xD;
&#xD;
        Eligible cohort entry dates:&#xD;
&#xD;
          -  For US MarketScan, 2012-2018&#xD;
&#xD;
          -  For Optum, 2012-2020&#xD;
&#xD;
          -  For Medicare Claims Database (Parts A, B and D), 2012-2017&#xD;
&#xD;
        Cohort entry date:&#xD;
&#xD;
          -  First TNFi or tofacitinib dispensation/administration date&#xD;
&#xD;
        Inclusion and Exclusion Criteria Common to RWE and RCT-duplicate Cohorts:&#xD;
&#xD;
          1. Inclusion Criteria&#xD;
&#xD;
               -  Patients treated with tofacitinib or TNF inhibitors in IBM MarketScan, Optum, and&#xD;
                  Medicare fee-for-service&#xD;
&#xD;
               -  A minimum of 365 days of continuous enrollment in health plan prior to (and&#xD;
                  including) the cohort entry date&#xD;
&#xD;
               -  Two diagnosis codes for RA in any setting in 365 days baseline period (diagnosis&#xD;
                  codes between 7 and 365 days apart)&#xD;
&#xD;
          2. Exclusion Criteria&#xD;
&#xD;
               -  Index drug in 365 days prior to cohort entry date (prevalent users)&#xD;
&#xD;
               -  Missing data on age or gender&#xD;
&#xD;
               -  Admission to nursing facility or hospice on or prior to cohort entry date (ever&#xD;
                  look-back)&#xD;
&#xD;
               -  Diagnosis of malignant cancer prior to cohort entry date (ever look-back period)&#xD;
&#xD;
               -  TNFi users with history of any Janus kinase (JAK) inhibitors (tofacitinib,&#xD;
                  upadacitinib, or baricitinib) (ever look-back period)&#xD;
&#xD;
               -  TNFi users initiating with more than one TNFi on same date&#xD;
&#xD;
               -  Tofacitinib users with a prescription of baricitinib, upadacitinib (ever&#xD;
                  look-back period)&#xD;
&#xD;
               -  Tofacitinib users initiating treatment on multiple JAK inhibitors on same day&#xD;
                  (tofacitinib and baricitinib, tofacitinib and upadacitinib)&#xD;
&#xD;
        Exclusion criteria specific to RWE cohorts:&#xD;
&#xD;
          -  Patients less than 18 years of age (MarketScan and Optum) and 65 years of age&#xD;
             (Medicare) at cohort entry&#xD;
&#xD;
        Inclusion criteria specific to RCT-duplicate cohorts:&#xD;
&#xD;
          -  Patients with at least one methotrexate dispensation (six months look-back period)&#xD;
&#xD;
          -  Patients with at least one cardiovascular risk factor (including smoking,&#xD;
             hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, family history&#xD;
             of ischemic heart disease) (one-year look-back period)&#xD;
&#xD;
        Exclusion criteria specific to RCT-duplicate cohorts:&#xD;
&#xD;
          -  Patients less than 50 years of age (MarketScan and Optum) and 65 years&#xD;
&#xD;
          -  Patients recently hospitalized with infections (30-day look-back period)&#xD;
&#xD;
          -  Pregnant patients (one year look-back period)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seoyoung C Kim, MD, ScD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham And Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Seoyoung C. Kim</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Golimumab</mesh_term>
    <mesh_term>Tumor Necrosis Factor Inhibitors</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04798287/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

